272 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
Download search resultsDownload the search results for:
United States, Texas | United States, Texas | cook children's (272 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting National Marrow Donor Program Long-Term Donor Follow-Up
Condition: Hematologic Neoplasms
Intervention:
2 Available Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide Lym-X-Sorb Oral Powder;   Drug: Ketoconazole
3 Recruiting Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Condition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: Drug: UX007 (triheptanoin);   Drug: Placebo Oil
4 Completed Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Condition: Leukemia
Intervention: Drug: Bendamustine
5 Unknown  Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency
Condition: Growth Hormone Deficiency
Intervention: Drug: Somatropin
6 Recruiting Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide/LXS Oral Powder;   Drug: Ketoconazole;   Drug: Vincristine
7 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
8 Unknown  Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Conditions: Septic Shock;   Thrombocytopenia;   Multiple Organ Failure
Intervention:
9 Recruiting Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Conditions: Vaso-occlusive Crisis;   Sickle Cell Disease
Interventions: Drug: MST-188;   Drug: Saline
10 Completed
Has Results
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Conditions: Sickle Cell Disease;   Iron Overload;   Hemolytic Anemia
Interventions: Drug: Deferasirox (ICL670);   Drug: Deferoxamine (DFO)
11 Completed
Has Results
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Condition: Patent Ductus Arteriosus (PDA)
Interventions: Device: Device closure with AMPLATZER Duct Occluder;   Other: Objective Performance Criteria
12 Active, not recruiting Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   NK Cell Lymphoblastic Leukemia
Interventions: Biological: Single Cord Blood Unit Transplantation;   Biological: Double Cord Blood Unit Transplantation
13 Recruiting An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
Condition: Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Intervention: Drug: Triheptanoin
14 Recruiting Baby Observational and Nutritional Study
Conditions: Cystic Fibrosis;   Growth Failure;   Exocrine Pancreatic Insufficiency
Interventions: Drug: Pancrelipase 3000 USP units of lipase;   Drug: Pancrelipase 750 USP units of lipase
15 Terminated Thrombolysis in Pediatric Stroke (TIPS)
Condition: Stroke
Intervention: Drug: Tissue plasminogen activator (Activase®)
16 Recruiting Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Condition: Extraocular Retinoblastoma
Interventions: Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: filgrastim;   Drug: carboplatin;   Drug: vincristine sulfate;   Drug: thiotepa;   Radiation: radiation therapy
17 Completed
Has Results
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
Conditions: Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions: Drug: idarubicin;   Drug: cytarabine;   Drug: bortezomib;   Drug: etoposide;   Other: laboratory biomarker analysis
18 Recruiting Fluorodopa F 18 in Congenital Hyperinsulinism
Condition: Congenital Hyperinsulinism
Intervention: Drug: Fluorodopa F 18
19 Suspended Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Radiation: external beam radiation therapy;   Drug: busulfan;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Biological: filgrastim;   Drug: mesna
20 Active, not recruiting Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Condition: Childhood Atypical Teratoid/Rhabdoid Tumor
Interventions: Procedure: autologous hematopoietic stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Drug: carboplatin;   Drug: thiotepa;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years